Inhaled dry powder respiratory therapeutic - Merck & Co.
Latest Information Update: 16 Jul 2016
$50 / €47 *
At a glance
- Originator Merck & Co
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Respiratory-tract-disorders in USA (Inhalation, Powder)
- 08 Jul 2013 MicroDose Therapeutx has been acquired by Teva Pharmaceutical Industries